© 2004 European Society of Cardiology
Use of NT-proBNP in routine testing and comparison to BNP
a Department III of Internal Medicine, University of Cologne Josef-Stelzmann Str. 9, 50924 Cologne, Germany
b Department of Clinical Chemistry, University of Cologne Germany
* Corresponding author. Tel.: +49-221-478-6207; Fax: +49-221-478-3763 E-mail address: christian.schneider{at}medizin.uni-koeln.de
 |
Abstract |
|---|
 Top Abstract 1. Introduction2. Methods3. Results4. DiscussionReferences |
|---|
Objectives: B-type natriuretic peptide (BNP) is a strong diagnostic predictor of left-ventricular (LV)-dysfunction. Recently, the aminoterminal portion of pro-BNP (NT-proBNP) has been introduced, which could be even more sensitive because of its longer half-life. The aim of this study was to evaluate the new marker NT-proBNP within a large, heterogeneous population of patients with suspected cardiovascular disease at risk of cardiovascular dysfunction and to compare it with the established diagnostic parameter BNP.
Subjects and methods: NT-proBNP and BNP were measured in 339 hospitalised patients undergoing diagnostic angiography (median age 66 years, 244 male vs. 95 female).
Results: Median values of NT-proBNP increased with worsening LV-dysfunction and higher NYHA class. The area under the receiver operator characteristics curve (AUC) of NT-proBNP for detecting severe systolic dysfunction or for detecting any systolic LV-dysfunction was 0.83 and 0.77, respectively. The latter improved (AUC=0.81) when patients with clinically relevant heart disease like valvular dysfunction were included, independent of the haemodynamic values. Compared to BNP, NT-proBNP tended to be more accurate in identifying lesser degrees of LV-dysfunction.
Conclusions: Even after optimisation of target criteria, there was still a substantial overlap of NT-proBNP values between patients with and without relevant heart disease. Therefore, NT-proBNP is not suitable as a screening test for LV-dysfunction in the community. Nevertheless, because of its good negative predictive value, NT-proBNP could be an easy and effective tool to rule out severe systolic LV-dysfunction in high risk patients. No clinically significant advantage of BNP testing could be found.
Key Words: B-type natriuretic peptide (BNP) • NT-proBNP • Heart failure • Left-ventricular dysfunction
Received November 26, 2003; Accepted December 22, 2003
|
1. Introduction |
|---|
|
TopAbstract1. Introduction2. Methods3. Results4. DiscussionReferences |
|---|
B-Type natriuretic peptide (BNP) is secreted mainly in the left ventricle in response to elevated wall tension [1]. Many publications describe BNP as an excellent marker of left ventricular (LV) function and a simple and effective tool to detect heart failure or LV-dysfunction [2–5]. Recently, the aminoterminal part of pro-BNP (NT-proBNP) was introduced, which is secreted in equivalent proportion to BNP. Because of its longer half-life, a higher sensitivity to detect early stage LV-dysfunction was supposed for NT-proBNP [6].
Most studies of NT-proBNP as a screening parameter for LV-dysfunction have either enrolled a small number of highly selected patients or have only assessed severe systolic LV-dysfunction by echocardiography in a community-based setting. The aims of the present study were first, to evaluate NT-proBNP as a marker of LV-dysfunction in a large, unselected population of patients with suspected cardiovascular disease. Secondly, we were interested in analysing the relationship of NT-proBNP to other cardiac diseases. Therefore, NT-proBNP was correlated with invasively determined haemodynamic variables and diagnoses. Thirdly, sensitivity and specificity of NT-proBNP were analysed in comparison to BNP.
|
2. Methods |
|---|
|
TopAbstract1. Introduction2. Methods3. Results4. DiscussionReferences |
|---|
2.1. Patients
Three hundred and thirty-nine consecutive hospital in-patients who underwent diagnostic cardiac catheterisation for clinical reasons were enrolled in our study. During cardiac catheterisation, left ventricular end-diastolic pressure (LVEDP) and mean pulmonary-arterial pressure (MPAP) were assessed if indicated. Also, the end-diastolic volume (EDV), the end-systolic volume (ESV) and the ejection fraction (EF) were determined angiographically by standard methods as described previously [7].
2.2. Natriuretic peptide measurements
The venous blood samples were drawn on the day before the catheterisation from clinically stable patients and were collected in EDTA containing tubes. Patients were rested supine for at least 30 min.
The samples were centrifuged within 1 h. One aliquot of the plasma was used for the NT-proBNP measurement (Elecsys proBNP, Roche Diagnostics, Germany), carried out on a Elecsys-2010 bench top analyser. Another aliquot was stored at –20 °C. These second aliquots were stored for 2 weeks and then used for the Shionoria BNP assay (CIS, Schering, Germany). The assays were done in accordance with the producer's manual.
2.3. Statistics
The analyses were done with the statistical analysis software SPSS 10.0 for windows. Variables were expressed as median with the minimum and the maximum value. Differences in the medians were compared by the Mann–Whitney-U test and the Kruskal–Wallis test if there were more than two subgroups, respectively. A P-value of <0.05 was considered statistically significant.
The correlation coefficients were calculated by the linear model of Pearson. Receiver operating characteristics (ROC) plot analysis was used to compare the diagnostic utility of both natriuretic peptides. The threshold for NT-proBNP and BNP was determined retrospectively by the ROC coordinates for a maximum sensitivity of >90% and minimal loss of specificity.
|
3. Results |
|---|
|
TopAbstract1. Introduction2. Methods3. Results4. DiscussionReferences |
|---|
Baseline characteristics of the 339 study subjects are shown in Table 1. The cardiological diagnoses are listed in Table 2.
|
|
3.1. Haemodynamics
Values of NT-proBNP were significantly elevated in individuals with reduced EF (<60%), elevated LVEDP (>12 mmHg) or elevated EDV (>220 ml) compared with participants without these features (all P<0.01). As shown in Table 3, the correlation of NT-proBNP with these measures of LV-function was significant but weak (P<0.05). The best correlation coefficients found were 0.44 and –0.47 for ESV and EF.
|
3.2. NYHA class and LV-dysfunction
Patients were categorized by New-York Heart Association (NYHA) classification for the severity of their exercise limitation at admission. With rising NYHA classes, the NT-proBNP values increased significantly (Fig. 1a). However, the median of NT-proBNP values of patients reported as NYHA class I was not significantly different from subjects classified as NYHA II.
|
60% and a left ventricular end-diastolic pressure LVEDP
16 mmHg, diastolic LV-dysfunction means LVEDP>16 mmHg and EFThe population was divided in four groups according to their LV-function (Fig. 1b): patients with normal LV-function, patients with diastolic dysfunction, patients with slight systolic and patients with severe systolic dysfunction. With worsening LV-function, the median values of NT-proBNP increased significantly (P<0.05), but with a large overlap between categories
3.3. Diagnostic performance
Table 4 shows the area under the ROC curve (AUC) value for NT-proBNP for the detection of LV-functional abnormalities. Patients with severe systolic LV-dysfunction (n=24) were defined by EF<40%, subjects with any systolic LV-dysfunction (n=72) were defined by EF<60% and finally probands with a systolic or diastolic LV-dysfunction (n=183) were defined by EF<60% or LVEDP>16 mmHg. The AUC rose with increasing LV-dysfunction. As NT-proBNP cut-offs were defined to achieve optimum sensitivity, the negative predictive values were high.
|
In clinical practice, LV-dysfunction may not be the only cause of heart failure. We therefore extended the target population to the diagnoses myocardial infarction, atrial flutter or fibrillation and relevant valvular heart disease in addition to the above defined LV-dysfunction (Table 4). Thereby the AUC and accordingly the specificity and positive predictive value of NT-proBNP increased.
3.4. Comparison with BNP
BNP was available in a subgroup of 149 patients. The corresponding logarithmic NT-proBNP and BNP values correlated highly significant (r=0.9, P<0.001, Fig. 2). The absolute values of NT-proBNP were by median factor 7.9 higher than the BNP values. There was no difference in this factor within subgroups defined by the degree of LV-dysfunction.
|
There was no difference for AUC for BNP and NT-proBNP in detecting severe or any systolic LV-dysfunction within these 149 probands. However, the AUC for detection of systolic or diastolic LV-dysfunction tended to be higher for NT-proBNP (Table 5).
|
|
4. Discussion |
|---|
|
TopAbstract1. Introduction2. Methods3. Results4. DiscussionReferences |
|---|
This is the first study to prospectively evaluate NT-proBNP as a serum marker of cardiac function in a large, heterogeneous patient population with invasively confirmed anatomic and haemodynamic diagnoses. Many NT-proBNP or BNP studies have included only small numbers of patients, focused on selected patients (for example only patients post myocardial infarction) or excluded patients because of renal failure or valvular disease [5,8–11]. The results of these studies cannot readily be transferred to the general population because the high co-morbidity and its effects on natriuretic peptides are not considered. In our study, we included 339 consecutive patients referred for diagnostic cardiac catheterisation. This constitutes a heterogeneous sample consisting of patients with stable as well as unstable coronary heart disease, patients with sinus rhythm or atrial fibrillation and patients with valvular dysfunction as well as inflammatory heart disease.
In the present study, we used a detailed classification of LV-dysfunction, defined by a combination of EF and LVEDP. As expected, NT-proBNP values increased with worsening LV-dysfunction. Nevertheless, there was a great overlap of NT-proBNP values between the different LV-function groups, especially for lesser degree dysfunction. The diagnostic performance indicated as AUC for NT-proBNP was 0.83 for detection of a severe systolic dysfunction, which is comparable with other large scale studies [4,12]. The AUC for detection of any systolic LV-dysfunction or systolic or diastolic dysfunction was 0.77 and 0.71, respectively. Even after inclusion of a third haemodynamic variable (EDV) for the definition of LV-dysfunction, the AUC was still not ideal (data not shown).
There are few data comparing BNP and NT-proBNP and these results are controversial [10,13]. Our comparison of the diagnostic performance of the natriuretic peptides showed a trend for NT-proBNP to be more accurate in identifying patients with diastolic LV-dysfunction. This could be attributed to the larger half life of NT-proBNP. However, due to the small study population these results must be regarded as preliminary.
Taken together, even after optimisation of target criterions, there was still a large overlap between subgroups leading to low specificity and positive predictive values of NT-proBNP. This result is in accordance with previous studies. Because of its good negative predictive value, NT-proBNP and BNP tests could be used effectively to exclude a relevant systolic LV-dysfunction within a high-risk cardiovascular population. Clinically significant differences between NT-proBNP and BNP could not be detected.
|
References |
|---|
|
TopAbstract1. Introduction2. Methods3. Results4. DiscussionReferences |
|---|
- Kinnunen P., Vuolteenaho O., Ruskoaho H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching. Endocrinology (1993) 132:1961–1970.
[Abstract/Free Full Text] - Nielsen O.W., McDonagh T.A., Robb S.D. Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. J Am Coll Cardiol (2003) 41:113–120.
[Abstract/Free Full Text] - Nakamura M., Endo H., Nasu M., Arakawa N., Segawa T., Hiramori K. Value of plasma B type natriuretic peptide measurement for heart disease screening in a Japanese population. Heart (2002) 87:131–135.
[Abstract/Free Full Text] - McDonagh T.A., Robb S.D., Murdoch D.R., et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet (1998) 351:9–13.[CrossRef][Web of Science][Medline]
- Krishnaswamy P., Lubien E., Clopton P., et al. Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction. Am J Med (2001) 111:274–279.[CrossRef][Web of Science][Medline]
- Hunt P.J., Yandle T.G., Nicholls M.G., Richards A.M., Espiner E.A. The amino-terminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma. Biochem Biophys Res Commun (1995) 214:1175–1183.[CrossRef][Web of Science][Medline]
- Schneider C.A., Helmig A.K., Baer F.M., Horst M., Erdmann E., Sechtem U. Significance of exercise-induced ST-segment elevation and T-wave pseudonormalization for improvement of function in healed Q-wave myocardial infarction. Am J Cardiol. (1998) 82:148–153.[CrossRef][Web of Science][Medline]
- Hunt P.J., Richards A.M., Nicholls M.G., Yandle T.G., Doughty R.N., Espiner E.A. Immunoreactive amino-terminal pro-brain natriuretic peptide (NT- PROBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf) (1997) 47:287–296.[CrossRef][Medline]
- Schulz H., Langvik T.A., Lund S.E., Smith J., Ahmadi N., Hall C. Radioimmunoassay for N-terminal probrain natriuretic peptide in human plasma. Scand J Clin Lab Invest (2001) 61:33–42.[CrossRef][Web of Science][Medline]
- Hammerer-Lercher A., Neubauer E., Muller S., Pachinger O., Puschendorf B., Mair J. Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Chim Acta (2001) 310:193–197.[CrossRef][Web of Science][Medline]
- Campbell D.J., Mitchelhill K.I., Schlicht S.M., Booth R.J. Plasma amino-terminal pro-brain natriuretic peptide: a novel approach to the diagnosis of cardiac dysfunction. J Card Fail (2000) 6:130–139.[Web of Science][Medline]
- Bay M., Kirk V., Parner J., et al. NT-proBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function. Heart (2003) 89:150–154.
[Abstract/Free Full Text] - Pfister R., Scholz M., Wielckens K., Erdmann E., Schneider C.A. The rank of natriuretic peptides NT-proBNP and BNP for the estimation of left-ventricular volume and function. Deut Med Wochenschr (2002) 127:2605–2609.[CrossRef]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F. I. Parthenakis, A. P. Patrianakos, C. N. Haritakis, E. A. Zacharis, E. G. Nyktari, and P. E. Vardas NT-proBNP response to dobutamine stress echocardiography predicts left ventricular contractile reserve in dilated cardiomyopathy Eur J Heart Fail, May 1, 2008; 10(5): 475 - 481. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Pfister, H. Diedrichs, A. Schiedermair, S. Rosenkranz, M. Hellmich, E. Erdmann, and C. A. Schneider Prognostic impact of NT-proBNP and renal function in comparison to contemporary multi-marker risk scores in heart failure patients Eur J Heart Fail, March 1, 2008; 10(3): 315 - 320. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Emdin, C. Passino, C. Prontera, M. Fontana, R. Poletti, A. Gabutti, C. Mammini, A. Giannoni, L. Zyw, G. Zucchelli, et al. Comparison of Brain Natriuretic Peptide (BNP) and Amino-Terminal ProBNP for Early Diagnosis of Heart Failure Clin. Chem., July 1, 2007; 53(7): 1289 - 1297. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Clerico, M. Fontana, L. Zyw, C. Passino, and M. Emdin Comparison of the Diagnostic Accuracy of Brain Natriuretic Peptide (BNP) and the N-Terminal Part of the Propeptide of BNP Immunoassays in Chronic and Acute Heart Failure: A Systematic Review Clin. Chem., May 1, 2007; 53(5): 813 - 822. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Ben-Dor, M. Haim, E. Rechavia, D. Murninkas, D. Harell, A. Porter, Z. Iakobishvili, A. Battler, and D. Hasdai Serum NT-proBNP Concentrations in the Early Phase Do Not Predict the Severity of Systolic or Diastolic Left Ventricular Dysfunction Among Patients With ST-Elevation Acute Myocardial Infarction Angiology, January 1, 2007; 57(6): 686 - 693. [Abstract] [PDF]
|
|
|
|
|
|
R. Cortes, M. Portoles, A. Salvador, V. Bertomeu, F. G. de Burgos, L. Martinez-Dolz, E. R. Lleti, V. Climent, A. Jordan, R. Paya, et al. Diagnostic and prognostic value of urine NT-proBNP levels in heart failure patients Eur J Heart Fail, October 1, 2006; 8(6): 621 - 627. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. R. Goldberg and M. Jessup Stage B Heart Failure: Management of Asymptomatic Left Ventricular Systolic Dysfunction Circulation, June 20, 2006; 113(24): 2851 - 2860. [Full Text] [PDF]
|
|
|
|
|
|
A. E. Malavazos, L. Morricone, A. Marocchi, F. Ermetici, B. Ambrosi, and M. M. Corsi N-terminal pro-B-type natriuretic Peptide and echocardiographic abnormalities in severely obese patients: correlation with visceral fat. Clin. Chem., June 1, 2006; 52(6): 1211 - 1213. [Full Text] [PDF]
|
|
|
|
|
|
P.A. Gould, J. D'Agostino, H.G. Schneider, and D.M. Kaye Influence of atrial fibrillation on cardiac brain natriuretic peptide release during haemodynamic stress in heart failure Eur J Heart Fail, May 1, 2006; 8(3): 263 - 269. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. C. Costello-Boerrigter, G. Boerrigter, M. M. Redfield, R. J. Rodeheffer, L. H. Urban, D. W. Mahoney, S. J. Jacobsen, D. M. Heublein, and J. C. Burnett Jr Amino-Terminal Pro-B-Type Natriuretic Peptide and B-Type Natriuretic Peptide in the General Community: Determinants and Detection of Left Ventricular Dysfunction J. Am. Coll. Cardiol., January 17, 2006; 47(2): 345 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Richards, M. G. Nicholls, E. A. Espiner, J. G. Lainchbury, R. W. Troughton, J. Elliott, C. M. Frampton, I. G. Crozier, T. G. Yandle, R. Doughty, et al. Comparison of B-Type Natriuretic Peptides for Assessment of Cardiac Function and Prognosis in Stable Ischemic Heart Disease J. Am. Coll. Cardiol., January 3, 2006; 47(1): 52 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tretjak, F. Verovnik, D. Benko, and M. Kozelj Tissue Doppler velocities of mitral annulus and NT-proBNP in patients with heart failure Eur J Heart Fail, June 1, 2005; 7(4): 520 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Hulsmann, R. Berger, D. Mortl, O. Gore, B. Meyer, and R. Pacher Incidence of normal values of natriuretic peptides in patients with chronic heart failure and impact on survival: A direct comparison of N-terminal atrial natriuretic peptide, N-terminal brain natriuretic peptide and brain natriuretic peptide Eur J Heart Fail, June 1, 2005; 7(4): 552 - 556. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. T. Bloomgarden The European Association for the Study of Diabetes Diabetes Care, May 1, 2005; 28(5): 1250 - 1257. [Full Text] [PDF]
|
|
|
|
|
|
K.-M. Hermann-Arnhof, U. Hanusch-Enserer, T. Kaestenbauer, T. Publig, A. Dunky, H. R. Rosen, R. Prager, and U. Koller N-Terminal Pro-B-Type Natriuretic Peptide as an Indicator of Possible Cardiovascular Disease in Severely Obese Individuals: Comparison with Patients in Different Stages of Heart Failure Clin. Chem., January 1, 2005; 51(1): 138 - 143. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||